Donafenib

A kinase inhibitor used in cancer treatment

Donafenib
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Donafenib is an oral multikinase inhibitor used in the treatment of certain types of cancer. It is a derivative of sorafenib, designed to improve efficacy and reduce side effects. Donafenib is primarily used in the treatment of hepatocellular carcinoma, a common type of liver cancer.

Mechanism of Action

Donafenib works by inhibiting multiple kinases involved in tumor cell proliferation and angiogenesis. It targets the RAF kinase family, VEGFR (vascular endothelial growth factor receptor), and PDGFR (platelet-derived growth factor receptor), among others. By blocking these pathways, donafenib reduces tumor growth and the formation of new blood vessels that supply the tumor.

Clinical Use

Donafenib is indicated for the treatment of advanced hepatocellular carcinoma. It is often prescribed when other treatments have failed or are not suitable. The drug is administered orally, allowing for convenient outpatient treatment.

Side Effects

Common side effects of donafenib include fatigue, diarrhea, hand-foot skin reaction, and hypertension. More severe adverse effects can include liver dysfunction and cardiac issues. Patients on donafenib require regular monitoring to manage these potential side effects.

Development and Approval

Donafenib was developed as an improvement over sorafenib, with modifications to enhance its pharmacokinetic properties and reduce toxicity. It has been approved for use in China and is undergoing further studies to expand its indications and improve its therapeutic profile.

Related Pages

• Sorafenib
• Hepatocellular carcinoma
• Kinase inhibitor
• Cancer treatment